



# Jennifer Raoul PhD Senior Counsel

T 613.787.3746 F 613.230.8842 Ottawa <u>JRaoul@blg.com</u> LinkedIn

<u>Health Care & Life Sciences</u> Patents

Jennifer brings over 20 years of specialized expertise to the pharmaceutical and biotechnology sectors as a registered Canadian patent agent and strategic IP advisor. In addition to drafting and prosecution, Jennifer develops comprehensive IP strategies for companies ranging from innovative startups to established industry leaders, focusing on building robust patent portfolios that align with business objectives.

Jennifer works closely with regulatory and litigation colleagues to ensure patent strategies align with strategies recommended under the regulatory frameworks that intersect with the Canadian patent system in respect of innovative drug products, including data protection, patent listing, patent term restoration, and price controls. Her comprehensive approach addresses patent procurement, optimized market exclusivity, freedom-to-operate analysis, and competitive intelligence to support informed decision-making throughout the entire product lifecycle.

Jennifer combines technical depth with business acumen, helping organizations leverage intellectual property as a strategic asset. Whether advising on portfolio architecture, due diligence for transactions, or risk mitigation strategies, she delivers practical solutions that advance client interests in Canada's dynamic life sciences marketplace.

## Experience

- Drafting and prosecuting patent applications in fields related to pharmaceuticals, biotechnology, therapeutics, diagnostics, medical devices, and chemistry.
- Advising on patentability, validity, infringement, and freedom-to-operate issues.



- Providing intellectual property due diligence and IP litigation support.
- Advising on issues related to patented medicines marketed in Canada.
- · Advising on international patent strategies and portfolio management.
- Advising and assisting with technology transfer.

## **Insights & Events**

 Author, "Regulatory context for patented pharmaceuticals and biotechnology drugs in Canada", BLG Article, December 2021

## **Beyond our Walls**

#### **Professional Involvement**

- Member, Intellectual Property Institute of Canada (IPIC)
- Member, Intellectual Property Owners Association (IPO)
- Member, International Federation of Intellectual Property Attorneys
- Member, BioNova: The Nova Scotia Biotechnology Industry Association
- Member, IPO's Pharmaceutical and Biotechnology Issues Committee
- Director, IPIC-McGill Understanding Patents Course for 2016

## Awards & Recognitions

- Recognized in the 2025 edition of The Best Lawyers in Canada™ (Health Care Law)
- Recognized in the 2024 edition (and since 2015) of Intellectual Asset Magazine's (IAM) Patent 1000 The World's Leading Patent Practitioners (Prosecution - Recommended).
- Edward Maybee Award for highest overall national standing in the Canadian patent agent qualifying exam.
- Marie F. Morency Award for highest national standing in the patent drafting portion of the Canadian patent agent qualifying examination.

### Education

- PhD (Doctorate of Philosophy in Pharmacology), Dalhousie University, 2004
- B.Sc. (Hons.), Dalhousie University, 1998

#### **BLG** | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers,



intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

#### blg.com

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.